The cardiopulmonary exercise test (CPET) provides functional prognostic parameters for patients with chronic heart failure (CHF), such as peak volume of oxygen (VO2) and minute ventilation/carbon dioxide production (VE/VCO2) slope. Sacubitril/valsartan (LCZ696) has been recently approved for CHF patients as it reduces cardiovascular (CV) deaths and hospitalization for heart failure (HF). However, the potential beneficial effects of this therapy on exercise performance have been poorly investigated to date.
Mapelli M, Vignati C, Paolillo S, De Martino F, Righini F, Agostoni P. Sacubitril/valsartan can improve exercise performance in systolic chronic heart failure patients: a case report. Curr Med Res Opin 2019 Mar;35(sup1):3-5. doi: 10.1080/03007995.2019.1576480.